摘要
目的对首发精神分裂症患者接受齐拉西酮治疗后的认知功能受影响情况进行分析研究,为临床用药提供参考。方法我院对64例首发精神分裂症患者开展了分析研究,将患者分成对照组和观察组,均有32例。观察组使用齐拉西酮,每天120~160 mg,对照组使用氯丙嗪治疗,每天300~450 mg。对两组患者临床认知功能变化情况和治疗效果进行对比分析。结果经过治疗后,观察组的治疗有效率是93.75%,对照组的治疗有效率是75.00%,差异有统计学意义(P<0.05)。治疗8周后,观察组的临床各项指标均比对照组优秀,两组结果差异有统计学意义(P<0.05)。结论首发精神分裂症患者临床中接受齐拉西酮治疗的临床效果比较突出,患者的认知功能得到了改善。
Objective To analyze the cognitive function of first-episode schizophrenics after ziprasidone treatment, so as to provide references for clinical medication. Methods 64 cases of first-episode schizophrenics were analyzed. The patients were divided into the control group and the observation group, with 32 cases in each group. The observation group was treated with ziprasone 120 to 160 mg a day, and the control group was treated with chlorpromazine from 300 to 450 mg a day. The changes of clinical cognitive function and therapeutic effect of the two groups were compared and analyzed. Results After treatment, the effective rate of treatment in the observation group was 93.75%, the effective rate of the control group was 75.00%, and the results were statistically different(P < 0.05). After eight weeks of treatment, the clinical indexes of the observation group were better than those of the control group, and the results of the two groups were statistically different(P < 0.05). Conclusion The clinical effect of ziprasidone in the treatment of first-episode schizophrenics is more prominent, and the cognitive function of patients has been improved.
出处
《中国卫生标准管理》
2018年第3期93-94,共2页
China Health Standard Management
关键词
首发
精神分裂症
齐拉西酮
认知功能
first onset
schizophrenia
ziprasidone
cognitive function
